PMID- 27966448
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20220409
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 2
DP  - 2017 Jan 10
TI  - Differential expression of peroxiredoxin 3 in laryngeal squamous cell carcinoma.
PG  - 3471-3480
LID - 10.18632/oncotarget.13838 [doi]
AB  - Peroxiredoxin (PRDX) proteins are involved in carcinogenesis. PRDX3, which is 
      predominantly localized in mitochondria and up-regulated in several human 
      cancers, seems to confer increased treatment resistance and aggressive 
      phenotypes. This study examined the expression profile of PRDX3 and its possible 
      clinical value in laryngeal squamous cell carcinoma (LSCC). The expression of 
      PRDX3 in LSCC samples was confirmed by Western blotting and further analyzed by 
      immunohistochemistry in LSCC samples of different clinical pathological stages. 
      The results showed that up-regulated expression of PRDX3 was observed in LSCC and 
      associated with poor differentiation (P < 0.01), primary tumor location, N 
      category and tumor stage (P < 0.05). Knockdown of PRDX3 in the Hep-2 laryngeal 
      carcinoma epithelial cell line significantly enhanced Hep-2 cells' apoptosis and 
      inhibited their proliferation and migration. Taken together, our results suggest 
      that PRDX3 has substantial clinical impact on the progression of LSCC and shed 
      new light on the role of PRDX3 in treatment resistance and aggressive phenotypes 
      in LSCC.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of 
      Qingdao University, Yantai, China.
AD  - Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Liu, Xuexia
AU  - Liu X
AD  - Department of Central Laboratory, Yuhuangding Hospital of Qingdao University, 
      Yantai, China.
FAU - Chen, Lei
AU  - Chen L
AD  - Department of Clinical Laboratory, Yuhuangding Hospital of Qingdao University, 
      Yantai, China.
FAU - Cai, Li
AU  - Cai L
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, 
      China.
FAU - Li, Ning
AU  - Li N
AD  - Department of Central Laboratory, Yuhuangding Hospital of Qingdao University, 
      Yantai, China.
FAU - Zhu, Peng
AU  - Zhu P
AD  - Department of Central Laboratory, Yuhuangding Hospital of Qingdao University, 
      Yantai, China.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Central Laboratory, Yuhuangding Hospital of Qingdao University, 
      Yantai, China.
FAU - Song, Xicheng
AU  - Song X
AD  - Department of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of 
      Qingdao University, Yantai, China.
FAU - Li, Guojun
AU  - Li G
AD  - Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - EC 1.11.1.15 (PRDX3 protein, human)
RN  - EC 1.11.1.15 (Peroxiredoxin III)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation
MH  - Combined Modality Therapy
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Peroxiredoxin III/*genetics/metabolism
PMC - PMC5356896
OTO - NOTNLM
OT  - Hep-2 cell line
OT  - laryngeal squamous cell carcinoma
OT  - oxidative stress
OT  - peroxiredoxin 3
COIS- CONFLICTs OF INTEREST The authors declare no conflicts of interest.
EDAT- 2016/12/15 06:00
MHDA- 2018/03/06 06:00
PMCR- 2017/01/10
CRDT- 2016/12/15 06:00
PHST- 2016/11/10 00:00 [received]
PHST- 2016/11/22 00:00 [accepted]
PHST- 2016/12/15 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2016/12/15 06:00 [entrez]
PHST- 2017/01/10 00:00 [pmc-release]
AID - 13838 [pii]
AID - 10.18632/oncotarget.13838 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jan 10;8(2):3471-3480. doi: 10.18632/oncotarget.13838.